Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

A Selective USP1–UAF1 Inhibitor Links Deubiquitination to DNA Damage Responses

USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses

USP39 Regulates DNA Damage Response and Chemo-Radiation Resistance by Deubiquitinating and Stabilizing CHK2.

USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response

USP37 Regulates DNA Damage Response Through Stabilizing and Deubiquitinating BLM

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging Chemotherapeutics.

HERC2-USP20 axis regulates DNA damage checkpoint through Claspin.

The E3 ubiquitin ligase DTX3L and the deubiquitinase USP28 fine-tune DNA double strand repair through mutual regulation of their protein levels

USP51 Deubiquitylates H2AK13,15ub and Regulates DNA Damage Response.

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

The deubiquitinase USP38 promotes NHEJ repair through regulation of HDAC1 activity and regulates cancer cell response to genotoxic insults.

USP49 participates in the DNA damage response by forming a positive feedback loop with p53

De-ubiquitination of SAMHD1 by USP7 promotes DNA damage repair to overcome oncogenic stress and affect chemotherapy sensitivity

Data from The Deubiquitinase USP38 Promotes NHEJ Repair through Regulation of HDAC1 Activity and Regulates Cancer Cell Response to Genotoxic Insults

USP1/UAF1 targets polyubiquitinated PCNA with an exo-cleavage mechanism that enriches for monoubiquitinated PCNA

Targeting deubiquitinase USP28 for cancer therapy

USP52 Regulates DNA End Resection and Chemosensitivity Through Removing Inhibitory Ubiquitination from CtIP

USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses.

USP25 Elevates SHLD2‐Mediated DNA Double‐Strand Break Repair and Regulates Chemoresponse in Cancer

The Emerging Role of Deubiquitinating Enzymes in Genomic Integrity, Diseases, and Therapeutics.